Since then, mutations in multiple components of the SHH signaling cascade have been identified in sporadic medulloblastoma, specifically inactivating mutations in PTCH1 and SUFU and activating mutations in SMO, together accounting for 15% of all cases 57, 59, 63, 75. This evidence concerns the gene SUFU and medulloblastoma.